Q3 Earnings Forecast for Geron Issued By Leerink Partnrs

Geron Corporation (NASDAQ:GERN) – Equities researchers at Leerink Partnrs issued their Q3 2026 EPS estimates for Geron in a report issued on Tuesday, August 12th. Leerink Partnrs analyst F. Khurshid expects that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The firm had revenue of $49.04 million for the quarter, compared to analysts’ expectations of $47.30 million. During the same quarter in the previous year, the company earned ($0.10) earnings per share. The company’s revenue for the quarter was up 5455.6% compared to the same quarter last year.

Other equities analysts have also recently issued research reports about the stock. The Goldman Sachs Group began coverage on shares of Geron in a research report on Thursday, July 10th. They set a “sell” rating and a $1.00 price target on the stock. Scotiabank cut shares of Geron from a “sector outperform” rating to a “sector perform” rating and reduced their price target for the company from $4.00 to $1.50 in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.19.

Geron Price Performance

GERN stock opened at $1.43 on Wednesday. Geron has a 12-month low of $1.09 and a 12-month high of $4.83. The company has a current ratio of 7.87, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $1.38 and its two-hundred day moving average price is $1.64. The stock has a market capitalization of $912.37 million, a price-to-earnings ratio of -11.00 and a beta of 0.73.

Institutional Investors Weigh In On Geron

Hedge funds have recently bought and sold shares of the business. Integrated Wealth Concepts LLC bought a new stake in Geron during the fourth quarter worth about $36,000. GF Fund Management CO. LTD. bought a new stake in Geron during the fourth quarter worth about $45,000. 111 Capital bought a new stake in Geron during the fourth quarter worth about $52,000. Fifth Lane Capital LP bought a new stake in Geron during the fourth quarter worth about $53,000. Finally, Harvest Investment Services LLC bought a new position in shares of Geron in the fourth quarter worth approximately $61,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.